Merck & Co. signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of the company’s experimental oral antiviral Covid-19 treatment, the U.S. drugmaker and the organization announced on Oct. 27.
Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.
Cortexyme Inc. said on Oct. 26 the company’s experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer’s disease in a study.
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is meeting Oct. 26 to discuss and recommend an emergency use authorization for the Pfizer-BioNTech vaccine for children 5 through 11 years of age.
To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).
AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.
The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.
Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).
Merck on Oct. 25 revealed positive results from two Phase III trials on a potential treatment for adults with HIV-1 infection and are virologically suppressed on different antiretroviral regimens (ART).
